Key result
Intravenous administration of NKH477 at /kg/min improved hemodynamic and clinical conditions in 71.4% of patients with acute heart failure compared to 34.3% in the lower-dose control group.
Why the study?
Does intravenous NKH477 improve hemodynamics and clinical symptoms in patients with acute heart failure?
RCT (n=78)
Double-blind
Randomized
Yes
Does intravenous NKH477 improve hemodynamics and clinical symptoms in patients with acute heart failure?
Intravenous NKH477 (colforsin daropate) safely and effectively improves hemodynamics and clinical symptoms in patients with acute heart failure.
Answers are grounded in this paper and cite their sources.
Supports intravenous NKH477 in acute heart failure; confirms hemodynamic and clinical benefit in this multicenter RCT.
We conducted a multi-center two-stage randomized double-blind placebo-controlled study to assess the efficacy and safety of NKH477. This drug, a newly synthesized water-soluble forskolin derivative, has been previously shown to improve hemodynamics and subjective symptoms in patients with acute heart failure.In the first stage (study 1), 78 patients with acute heart failure were randomly assigned to receive either NKH477 by intravenous administration at 0.5μg/kg/min for 30 min or a lower dose of NKH477 as a “substitute” placebo, namely 0.2μg/kg/min for 30 min. The second stage (study 2) began within 10 min after the end of dosing in study 1. Forty-seven patients were randomly assigned to either continue treatment with NKH477 at 0.5 μg/kg/min for 1 hr or toreceive matching vehicle placebo.In study 1, the percentage improvement in hemodynamic and subjective and objec tive conditions in the control group as judged by attending physicians was 34.3 %. In contrast, improvement in the NKH477 group was 71.4 %, this difference being significant (p<0.01). No significant difference was seen between the groups with respect to side effects and abnormal changes in laboratory data. Usefulness as rated according to the above assessment was 31.6 % in the lower dose group and 71.4 % in the NKH477 group, this difference again being significant (p<0.01).Moreover, in study 2, the percentage improvement was even greater in the NKH477 group compared to the placebo group, at 82.4 % and 16.7 %, respectively. Again, there was no significant difference between the groups with respect to side effects and abnor mal changes in laboratory data. Respective usefulness values were 76.5 % and 16.7 %, this difference again being significant (p<0.01).These results indicate that NKH477 is useful and safe in the treatment of acute heart failure.
No takes yet. Share an insight, caveat, or question.
Hosoda et al. (1995) conducted an RCT in Acute heart failure (n=78). NKH477 vs. 0.2 µg/kg/min NKH477 (Study 1) / Placebo (Study 2) was evaluated on Percentage improvement in hemodynamic and subjective and objective conditions (p=<0.01). Intravenous administration of NKH477 at /kg/min improved hemodynamic and clinical conditions in 71.4% of patients with acute heart failure compared to 34.3% in the lower-dose control group.
Synapse has enriched 10 related papers. Consider them for comparative context: